Illumina, Inc. v. Ariosa Diagnostics, Inc., No. 19-1419 (Fed. Cir. Mar. 17, 2020)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Illumina, Inc. and Sequenom, Inc. (collectively, “Illu- mina”) appeal from a decision of the United States District Court for the Northern District of California that claims 1– 2, 4– 5, and 9– 10 of U.S. Patent 9,580,751 (the “’751 pa- tent”) and claims 1 –2 and 10–14 of U.S. Patent 9,738,931 (the “’931 patent”) are invalid under 35 U.S.C. § 101 as di- rected to an ineligible natural phenomenon. Illumina, Inc. v. Ariosa Diagnostics, Inc., 356 F. Supp. 3d 925 (N.D. Cal. 2018) (“Decision”).